Our purpose was to present the clinical feasibility of TBI with helical tomotherapy (HT) in four patients with AML. Treatment planning, delivery, dose verification and summation, toxicity and patient outcomes for each patient are presented. TBI prescription was set in such a manner that 80% of the clinical target volume received 12 Gy in six fractions, at two fractions per day. Dose reconstruction was carried out by recontouring the regions of interest in the daily pretreatment megavoltage computed tomography of each individual fraction and calculating its corresponding dose. A deformable registration model was used for dose summation of all individual fractions. Differences between planned and delivered doses were calculated. Average planned and delivered doses to the regions of interest differed by up to 2.7%. TBI toxicity was limited to radiotherapy oncology group grade 1 dermatitis in all patients and grade 1 headache in one patient. Two patients are alive with no evidence of disease and no GVHD. Two patients died of GVHD, but there was no evidence of disease at the time of death. We conclude that HT simplifies the process of TBI. Dose verification is possible with HT showing small differences between plan and delivered doses.
Introduction
TBI is widely used as a preparatory regime before BMT. In BMT, TBI serves a dual purpose. One is cell kill, which contributes to eradication of malignant cells. The other is immunosuppression to decrease the risk of GVHD. However, mHA differences in allogeneic BMT facilitate a graft vs tumor effect that enhances malignant cell kill. Clinical data, [1] [2] [3] [4] [5] as well as strict quality assurance, 6 have led to improvement in the TBI technique. Nevertheless, current accepted techniques of TBI are laborious, time-consuming and cumbersome because of the use of heavy blocks, compensators, low dose rates, beam spoilers and extended source to skin distances. In addition, dose prescription and verification is usually limited to single-point measurements.
Critical organ sparing is inadequate, with wide variation of the actual dose distributions within the same patient and from patient to patient. The advent of dynamic conformal radiotherapy in the form of helical tomotherapy (HT) offers a new and more quantitative paradigm for TBI dose planning and delivery. In TBI with HT, there is no need for treatment devices or extended source to skin distances. Non-clinical dosimetric studies of TBI with HT 7, 8 have shown that HT offers a precise homogeneous radiation dose to the target while allowing significant reduction of dose to critical organs.
In this work, we present the clinical feasibility of TBI with HT in four patients with AML. Treatment planning, delivery, dose verification and summation, toxicity and patient outcomes for each patient are presented.
Materials and methods

Patients
The characteristics and details of pre-TBI chemotherapy of four patients with a diagnosis of AML are given in Table 1 . Initial induction of all patients was essentially with the 7 þ 3 regime (cytarabine þ DNR or idarubicin). Other drugs were used in addition to the 7 þ 3 regime during the initial induction period as shown in Table 1 . If the patient was not in initial remission or had relapsed, the patient was treated with the FLAG (fludarabine, cytarabine and G-CSF) regime. These four patients received TBI with HT as part of their preparatory regime before allo-SCT. All patients received antiemetic prophylaxis before daily TBI fraction with either ondansetron (three patients) or promethazine (one patient). Our current TBI program for AML prescribes 12 Gy in six equal fractions at two fractions per day, over 3 days, and with a minimum 6-h interfraction interval. Three patients had chemotherapy induction for clearing the BM of leukemic cells before TBI. One patient was refractory to induction therapy and proceeded to transplant without being in remission. All patients received allogeneic transplantation. Three out of four patients received full match-related transplants. One patient received a match-unrelated donor transplant.
CT-simulation
Patient immobilization was achieved by the use of vacuum body bags and thermoplastic head to shoulder masks. Each patient had a total of 4 kVCT simulations with 3 mm slice thickness. These image sets included a 4D CT of the lungs, a 4D CT of the kidneys, a head-to-knee-level CT and a CT of the remainder of the lower extremities. The HT unit can treat targets up to 160 cm in length. Hence, the latter two image sets were used to generate two HT plans, one for treatment from head to knee level and the other for treatment of the remainder of the lower extremities. The 4D CTs of the lungs and kidneys were obtained in order to generate maximum-intensity projections of the kidneys and lungs to be registered with the head-to-knee CT image set for the delineation of organs at risk (OAR).
Clinical target volume (CTV) and organ at risk (OAR) segmentation For each patient, the lungs and kidneys were outlined as OARs. These were outlined on the 4D CT studies of the lungs and kidneys. The CTV for each patient was defined as the whole body, excluding the OARs.
TBI planning
An HT plan for TBI was generated for each patient. The prescription was set such that 80% of the CTV was covered by the prescription isodose of 12 Gy using the 5 cm jaw width and normal grid size (2-4 mm voxel). Planning proceeded as described by Hui et al. 7 To start the planning process, TERMA (total energy released per unit mass) iterations were performed to attempt to find the lowest modulation factor and loosest pitch capable of maintaining the dose-volume histogram characteristics of a plan with a high modulation factor and tight pitch. This resulted in a modulation factor and a pitch of 2 and 0.287, respectively. In one plan a pitch of 0.43 was used, but this resulted in a marked thread effect. 9 Initial dose calculation took between 8 and 10 h. At the conclusion of the initial dose calculations, the initial dose distribution was optimized by adjustment of constraints such as minimum, maximum, dose-volume histogram dose and the corresponding penalties. Approximately 15-20 iterations were needed to view the result of the constraint adjustment. The optimization process took from 45 min to 1 h. For the treatment planning of the remainder of the lower extremities, the same jaw width, modulation factor and pitch were used. At the time of treatment planning, a radio-opaque marker was placed just superior to the patella to define the upper border of the lower extremity treatment plan. Results of the lower extremity plans are not shown in this work. Abbreviations: 7+3 ¼ cytarabine for 7 days and DNR or idarubicin for 3 days; FLAG ¼ fludarabine, cytarabine and G-CSF. a After leukemia recurrence or failure to achieve initial remission with the 7 + 3 regime, patients were re-induced with FLAG. Patient 4 received clofarabine after failure to achieve remission with 7 +3 and FLAG. Remission was not obtained on this patient and he was deemed refractory to therapy. b This patient received additional cytarabine during the induction process.
13. The prescription for this plan was set such that 80% of the CTV (whole body minus kidneys and lungs) was covered by the 12 Gy iso-dose volume.
Planning average doses to OAR were set not to exceed 8 Gy and 10 Gy to the lungs and the kidneys, respectively. Notice the decrease in dose in the lungs and kidneys as well as the prescription iso-dose volume of 12 Gy.
Planning average doses to OAR were set not to exceed 8 Gy and 10 Gy to the lungs and kidneys, respectively.
A typical isodose distribution for one of the treated patients is seen in Figure 1 . Figure 2 shows the corresponding dose-volume histogram to the patient shown in Figure 1 .
Quality assurance (QA) of TBI treatment plan QA of the tomotherapy treatment plan for each patient was performed by a qualified medical physicist to assure that the planning dose could be delivered with high accuracy. A cylindrical phantom was used in the QA procedure. It was imaged on the CT simulator scanner and imported into the tomotherapy planning station. The patient treatment plan was transferred onto the phantom image and dose distribution based on the phantom material and geometry was calculated. A conventional ion chamber-film QA procedure was adopted to carry out the measurement; that is, the ionization chamber was inserted to the isocenter and the EDR2 film was sandwiched on the coronal plane between two hemispheres of the phantom. The point dose measurement from the ion chamber was compared with that of the QA plan and the dose profile obtained from the film measurement was similarly compared. 10 The treatment plan obtained was rejected if the dose difference between the planned and measured doses was larger than 5%. Because of the size of the CTV, 2-3 QA plans were applied to the phantom, and doses were measured along the longitudinal axis of each patient.
Treatment delivery
Patients were placed on the treatment couch in the treatment planning position. Each patient underwent a megavoltage computed tomography (MVCT) for treatment alignment before each fraction using coarse mode (6 mm slice thickness). Automatic kVCT to MVCT fusion was performed on the basis of the regions of interest. Manual fusion was performed on all patients to improve the registration accuracy by verifying axial, coronal and sagittal images for each study. Once the registration was approved, the couch was positioned to the determined registration coordinates and treatment was started.
Delivered dose reconstruction and deformable registration
As the planned dose may not be equal to the delivered dose because of anatomical variations from fraction to fraction, each dose fraction was reconstructed and then summed in order to obtain the actual dose delivered (verification dose). Verification dose was calculated in two steps. First, the treatment dose for an individual fraction was calculated (normal grid size with voxel size of 2-4 mm) using the Helical Tomotherapy Planned Adaptive Station (Tomotherapy Inc, Madison, WI, USA) on the basis of the treatment sinograms and MVCT acquired before each treatment. The second step was the voxel-to-voxel summation of doses from individual fractions taking into account the interfraction anatomy variations. Deformable registration between the MVCT and the planning CT was used for accurate mapping of voxels. In this study, a B-Spline deformable registration model was used with 15 Â 15 Â 15 grid placed on the input images to perform the registration. The advantage of the B-Spline model is that the B-Spline grids are locally controlled, such that the displacement of an interpolation point is influenced only by that of the closest grid points. This makes the process efficient in describing local deformation. To achieve an accurate and efficient computation, the Mattes mutual information metric function was chosen and then optimized with the limited-memory Broyden-Fletcher-Goldfarb-Shanno algorithm with respect to the transform parameters. The optimizer iteratively varied the parameters and searched for the global minimum of the metric function. After successful registration, the resultant deformation vectors were used to deform the individual verification doses and a total dose summation was accomplished. The reconstructed dose distribution and its dosimetric parameters were compared with those of the original treatment plan. 
Results
Results are summarized in Table 2 .
Response to induction Patient 1 failed to achieve remission to the 7 þ 3 regime þ gemtuzumab. His therapy was changed to the FLAG regime, which was successful in providing remission to the patient. He then proceeded to transplantation. Patient 2 achieved remission with the initial 7 þ 3 induction regime. This patient also received cytarabine and idarubicin during induction. The patient relapsed approximately 3 months later and was reinduced successfully with the FLAG regime. She then proceeded to be transplanted.
Patient 3 failed to achieve remission with the 7 þ 3 regime. His therapy was changed to the FLAG regime, which was successful in clearing his BM. However, he developed biopsy-proven dermal leukemic infiltrates. His BM continued to be clear at that time. He then proceeded to transplantation.
Patient 4 never achieved remission with either the initial 7 þ 3 therapy or with the subsequent FLAG regime. He also received clofarabine after failing FLAG-idarubicin therapy. He was considered refractory to therapy and proceeded to be transplanted.
Beam-on times TBI beam-on times ranged from 19 to 23 min (see Table 2 ).
CTV doses
Average planned and delivered CTV doses ranged from 12.1 to 12.4 Gy and 11.9 to 12.3 Gy, respectively. CTV s.d.s.
for the planned and delivered doses ranged from 0.6 to 0.8 Gy (see Table 2 ).
Dose homogeneity index (DHI)
The planned and delivered DHI was defined as the ratio of the dose received by 90% of the CTV to the minimum dose received by the 'hottest' 10% of the CTV. 11 The ideal value for the DHI is 1. For the four patients in this work, the planned and delivered dose DHI ranged from 0.91 to 0.94 and from 0.90 to 0.95, respectively (see Table 2 ).
OAR doses
Average planned and delivered lung doses ranged from 6.6 to 7.4 Gy and 6.5 to 7.4 Gy, respectively. Average planned and delivered left kidney doses ranged from 7.4 to 8.7 Gy and 7.2 to 8.6 Gy, respectively. Average planned and delivered right kidney doses ranged from 7.5 to 8.6 Gy and 7.3 to 8.5 Gy, respectively (see Table 2 ).
Toxicity during TBI
Toxicity during TBI is summarized in Table 3 . All patients experienced radiotherapy oncology group grade 1 asymptomatic radiation dermatitis and one patient experienced radiotherapy oncology group grade 1 headache. For this patient, treatment of his headache was not necessary. Table 2 summarizes the comparison between planned and delivered TBI doses and dose homogeneity indices.
Planned and delivered dose comparison
The difference between planned and delivered maximum, minimum, average doses and DHI for the CTV of the four patients ranged from À0.7 to 0.7%, À2.2 to 6%, À1.7 to 0% and À4.4 to 0%, respectively. For the average lung Table 2 Comparison of planned dose, delivered doses and dose homogeneity index in four patients with AML treated with TBI HT Abbreviations: CTV ¼ clinical target volume; HT ¼ helical tomotherapy. a The dose homogeneity index was defined as the ratio of the dose received by 90% of the CTV to the minimum dose received by the 'hottest' 10% of the CTV. 10 dose, the difference between planned and delivered doses ranged from À1.5 to 2.7%. For the left and right kidneys, the average dose difference ranged from À2.7 to 1.3% and À2.7 and 2.6%, respectively.
Patient outcome
Patient outcome is summarized in Table 3 . Patient outcome was measured from the time that TBI ended to the time of last follow-up. Follow-up ranged from 5 to 9 months, with a median of 7 months. Two patients are alive without AML or GVHD at 11 and 12 months. Two died of GVHD at 5 and 6 months with no evidence of AML.
Discussion
Our results confirm previous publications of TBI with HT. 7, 8 These studies were conducted in phantoms or CT simulations from patients. That is, no actual patients were treated with HT TBI in those studies. This study treated real patients with HT TBI. In addition, we performed a reconstruction of delivered total doses and a comparison with planned doses.
Conventional TBI techniques are essentially parallelopposed AP-PA or lateral ports, with patients lying either in the decubitus or in the supine positions. 12, 13 Large dose variation occurs throughout the whole body secondary to different thicknesses at different levels of the patient's body. In conventional TBI techniques, the prescription is targeted to one point at midplane, usually at the level of the umbilicus. The head and neck and ankles receive a much higher dose than prescribed because of the lack of tissue to attenuate the beam. This dose variation can be up to 50% with parallel-opposed lateral techniques. 6 Tissue compensators are used to partially correct for the dose inhomogeneity. Positioning of these tissue compensators lacks precision. For example, if the compensator is used for the head and neck region, it is important that it does not cover part of the shoulders, thus decreasing the dose to this region. There may also be a shift in the patient treatment position (as patients are not immobilized in the conventional technique) or in the compensator position. Our results with HT showed the lowest delivered DHI to be 0.90, reflecting high dose homogeneity within the CTV.
Skin or superficial dose in conventional TBI is addressed by placing a beam spoiler 14 in the path of the beam. The interaction of this beam spoiler with the incoming photons generates scattered electrons that increase the surface dose to the patient. This large 2 cm-thick acrylic screen is placed approximately 10 cm from the patient. Alternatively, 8 mm-thick blankets of tissue equivalent bolus can be used. It is nearly impossible to apply the bolus without air pockets between the bolus and the patient.
Lung toxicity secondary to TBI can be a serious problem. Without lung compensators or blocks, tissue inhomogeneities have been reported to be in the range of 10-24%. 6 Reproducibility of the lung block position is crucial. Techniques have been described to increase the accuracy of lung block placement. 15, 16 Some institutions boost the chest wall under the lung block with an electron beam, thus adding an additional layer of complexity to the procedure. 17, 18 Besides, the midlung dose from the electron beam is usually very high, as a higher energy electron beam is used. Lung blocks may not be needed if the lateral technique is used, as the arms function as compensators. At best, this is a very crude way to compensate for lung tissue heterogeneity. Nevertheless, other compensators are needed to account for varying patient thickness. Our results with HT TBI showed that the delivered average doses to the lungs were between À1.5 and 2.7% of the planned doses. This was achieved without lung blocks or reduced dose rates for lung protection, and with consistently precise immobilization of the patient.
Renal toxicity from TBI is also a serious problem in BMT, as patients generally receive other therapy with nephrotoxicity ranging from chemotherapy to antifungals and antibiotics. Kidney tolerance to fractionated TBI doses is 14 Gy in adults and o12 Gy in children. [19] [20] [21] Renal tolerance to radiation may be significantly lowered with the use of chemotherapy. 22 Kidney blocks may be used in order to reduce the dose to these organs. 23, 24 Our results with HT TBI showed that delivered average doses to the kidneys were between À2.7 and 2.6% and À2.7 and 1.3% of the planned doses for the right and left kidneys, respectively. This was achieved without kidney blocks.
Dose rate is a factor that influences the biological effects of TBI. 25 Low dose rates in the range of 0.05-0.2 Gy per min are required in many clinical protocols, as a low dose rate in TBI is thought to offer protection against the development of interstitial pneumonitis. [26] [27] [28] However, an analysis of 26 patient cohorts receiving TBI as preparatory regimes before BMT from 20 institutions does not support the concept that increasing the dose rate will result in a higher risk of interstitial pneumonitis. 29 Investigators have raised the concern of circulating clonogens receiving a reduced dose of radiation by traveling outside the radiation beam when sweeping or scanning beams are used. 30, 31 Before TBI, patients receive chemotherapy, but clonogens may remain in circulation. The main difference between TBI with HT and conventional delivery is that, in HT, only one slice is irradiated at a time, whereas in conventional delivery the entire CTV is irradiated at the same time. Nevertheless, TBI techniques using a horizontal scanning beam with the patient being stationary, a stationary beam with the patient moving horizontally or a sweeping beam with the patient being stationary have been described without compromising the patient's outcome. [32] [33] [34] In each of these techniques, only a part of the CTV is irradiated at any one time.
In vivo dose verification is recommended for new TBI techniques. In conventional TBI, this is usually carried out with the use of thermoluminiscent dosimeters , ionization chambers and diodes. As reported here, in TBI with HT, dose verification of each individual treatment fraction is possible; hence, the differences between planned and delivered doses can be evaluated. Our results indicate that for the four presented patients, the largest difference between planned and delivered average dose to the CTV was À1.7%.
In this work, we have shown that it is feasible to use HT to deliver clinical TBI. HT delivers an elegant and dosimetrically superior solution to the cumbersome conventional techniques of TBI. With HT, there is no need for blocks or compensators, low dose rates, extended source to skin distances, beam spoilers or uncomfortable patient positioning (that is, lateral technique). In addition, dose verification is possible with HT by recontouring regions of interest in each pretreatment MVCT and reconstructing the summed delivered dose. The comparison of the reconstructed with the planned dose was carried out in 3-D on the basis of dose-volume histogram, ROI statistics and viewed dose distribution superimposed on CT axial cuts. We are able to show that the delivered dose and the planned dose differ minutely in these four cases. Our patient population in this work is very small, hence more patients and longer follow-up are needed to make firm conclusions regarding patient outcome. Nevertheless, it is, to our knowledge, the first report of the clinical feasibility of TBI with HT in an actual clinical setting with limited toxicities, reopening the debate of the potential benefits of TBI dose escalation. 35 
Conflict of interest
The authors declare no conflict of interest.
